

Attorney Docket No. 2005_0199A
Serial No. 10/523,982
February 8, 2007

AMENDMENTS TO THE CLAIMS

1. (Currently amended) A method of screening for a substance which serves as the active ingredient in a drug for an agent for the treatment of obesity and/or diabetes, which method comprises:

treating cells or an animal with a candidate substance and specifying the candidate substance ~~fulfilling~~ having one or more of the following ~~requirements~~ properties as the target active ingredient substance:

- ~~— (a) — increasing the expression level of a ligand factor ERRL1 for a nuclear receptor ERR;~~
- ~~— (b) — increasing the transcriptional activity of the nuclear receptor ERR;~~
- ~~— (c) — promoting the binding of ERRL1 to ERR; and~~
- ~~— (d) — increasing the expression level of an MCAD gene product.~~

(a) promoting the binding of an estrogen related receptor ligand 1 (ERRL1) to estrogen related receptor (ERR); and

(b) increasing the transcriptional activity of ERR, as same as the action of ERRL1 for ERR.

2. (Currently amended) ~~A drug for~~ A pharmaceutical composition for the treatment of obesity and/or diabetes comprising as the active ingredient one or more substances specified by the method of claim 1.

3. (Currently amended) ~~A transgenic non-human animal having~~ mouse comprising a purified polynucleotide encoding a ligand factor ERRL1 for a nuclear receptor ERR in its genomic DNA and overexpressing the ligand factor ERRL1, wherein said transgenic mouse is lean and hyperphagic.